Begoña Quintana-Villamandos

Dr. Begoña Quintana-Villamandos


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2013 in Hypertension Research
Verified
Journal Article
Open access
PDF file
BQBegoña Quintana-Villamandos
Begoña Quintana-Villamandos
MDMaría Jesús Delgado-Martos
María Jesús Delgado-Martos
JSJose Javier Sánchez-Hernández
Jose Javier Sánchez-Hernández
JDJose Juan Gómez de Diego
Jose Juan Gómez de Diego
MFMaría del Carmen Fernández-Criado
María del Carmen Fernández-Criado
EDEmilio Delgado-Baeza
Emilio Delgado-Baeza
Certain β-adrenergic blockers have proven useful in the regression of ventricular remodeling when administered as long-term treatment. However, early regression of left ventricular hypertrophy (LVH) has not been reported, following short-term administration of these drugs. We tested the hypothesis that short-term administration of the cardioselective β-blocker esmolol induces early regression of LVH in spontaneously hypertensive rats (SHR). Fourteen-month-old male SHRs were treated i.v. with vehicle (SHR) or esmolol (SHR-E) (300 μg kg−1 min−1). Age-matched vehicle-treated male Wistar-Kyoto (WKY) rats served as controls. After 48 h, left ventricular morphology and function were assessed using M-mode echocardiograms (left ventricular mass index (LVMI), ejection fraction and transmitral Doppler (early-to-atrial filling velocity ratio (E/A), E-wave deceleration time (Edec time)). The standardized uptake value (SUV) was applied to evaluate FDG (2-deoxy-2[18F]fluoro-D-glucose) uptake by the heart using PET/CT. Left ventricular subendocardial and subepicardial biopsies were taken to analyze changes in cross-sectional area (CSA) of left ventricular cardiomyocytes and the fibrosis was expressed as collagen volume fraction (CVF). LVMI was lower in SHR-E with respect to SHR (P=0.009). There were no significant differences in EF, E/A ratio or Edec time in SHR-E compared with SHR (P=0.17, 0.55 and P=0.80, respectively). PET acquisitions in SHR-E showed lower 18F-FDG uptake than SHR (P=0.003). Interestingly, there were no significant differences in SUV in either SHR-E or WKY (P=0.63). CSA in subendocardial and subepicardial regions was minor in SHR-E with respect to SHR (P<0.001), and there were no significant differences in CVF between both groups. Esmolol reverses early LVH in the SHR model of stable compensated ventricular hypertrophy. This is the first study to associate early regression of LVH with administration of a short-term β-blocker.

21 November 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BQBegoña Quintana-Villamandos
Begoña Quintana-Villamandos
JDJose Juan Juan Gomez de Diego
Jose Juan Juan Gomez de Diego
MDMaría Jesús Delgado-Martos
María Jesús Delgado-Martos
DMDavid Muñoz-Valverde
David Muñoz-Valverde
MMMª Luisa Soto Montenegro
Mª Luisa Soto Montenegro
EDEmilio Delgado-Baeza
Emilio Delgado-Baeza
Left ventricular hypertrophy (LVH) in hypertension is associated with a greater risk of sustained supraventricular/atrial arrhythmias. Dronedarone is an antiarrhythmic agent that was recently approved for the treatment of atrial fibrillation. However, its effect on early regression of LVH has not been reported. We tested the hypothesis that short-term administration of dronedarone induces early regression of LVH in spontaneously hypertensive rats (SHRs). Ten-month-old male SHRs were randomly assigned to an intervention group (SHR-D), where animals received dronedarone treatment (100 mg/kg) for a period of 14 days, or to a control group (SHR) where rats were given vehicle. A third group with normotensive control rats (WKY) was also added. At the end of the treatment with dronedarone we studied the cardiac anatomy and function in all the rats using transthoracic echocardiogram, cardiac metabolism using the PET/CT study (2-deoxy-2[18F]fluoro-D-glucose) and cardiac structure by histological analysis of myocyte size and collagen content. The hypertensive vehicle treated SHR rats developed the classic cardiac pattern of hypertensive cardiomyopathy as expected for the experimental model, with increases in left ventricular wall thickness, a metabolic shift towards an increase in glucose use and increases in myocyte and collagen content. However, the SHR-D rats showed statistically significant lower values in comparison to SHR group for septal wall thickness, posterior wall thickness, ventricular mass, glucose myocardial uptake, size of left ventricular cardiomyocytes and collagen content. All these values obtained in SHR-D rats were similar to the values measured in the normotensive WKY control group. The results suggest by three alternative and complementary ways (analysis of anatomy and cardiac function, metabolism and histological structure) that dronedarone has the potential to reverse the LVH induced by arterial hypertension in the SHR model of compensated ventricular hypertrophy.

1 January 2014 in BioMed Research International
Verified
Journal Article
Open access
AAAna Arnalich-Montiel
Ana Arnalich-Montiel
MGMaría Carmen González
María Carmen González
EDEmilio Delgado-Baeza
Emilio Delgado-Baeza
MDMaría Jesús Delgado-Martos
María Jesús Delgado-Martos
LCLuis Condezo-Hoyos
Luis Condezo-Hoyos
BQBegoña Quintana-Villamandos
Begoña Quintana-Villamandos
The aim of this study was to assess the effects of short-term esmolol therapy on coronary artery structure and function and plasma oxidative stress in spontaneously hypertensive rats (SHR). For this purpose, 14-month-old male SHR were treated for 48 hours with esmolol (SHR-E, 300 μg/kg/min). Age-matched untreated male SHR and Wistar Kyoto rats (WKY) were used as hypertensive and normotensive controls, respectively. At the end of intervention we performed a histological study to analyze coronary artery wall width (WW), wall-to-lumen ratio (W/L), and media cross-sectional area (MCSA). Dose-response curves for acetylcholine (ACh) and sodium nitroprusside were constructed. We also assessed several plasma oxidative stress biomarkers, namely, superoxide scavenging activity (SOSA), nitrites, and total antioxidant capacity (TAC). We observed a significant reduction in WW (P<0.001), W/L (P<0.05), and MCSA (P<0.01) and improved endothelium-dependent relaxation (AUCSHR-E=201.2±33versusAUCSHR=97.5±21,P<0.05) in SHR-E compared with untreated SHR; no differences were observed for WW, MCSA, and endothelium-dependent relaxation by ACh at higher concentrations (10−6to 10−4 mol/l) for SHR-E with respect to WKY. SOSA (P<0.001) and nitrite (P<0.01) values were significantly higher in SHR-E than in untreated SHR; however, TAC did not increase after treatment with esmolol. Esmolol improves early coronary artery remodeling in SHR.

18 February 2018 in BioMed Research International
Verified
Journal Article
Open access
PDF file
BQBegoña Quintana-Villamandos
Begoña Quintana-Villamandos
DGDavid A. Goukassian
David A. Goukassian
SSSharath P. Sasi
Sharath P. Sasi
EDEmilio Delgado-Baeza
Emilio Delgado-Baeza
Our group has previously demonstrated that short-term treatment with esmolol reduces left ventricular hypertrophy (LVH) in spontaneously hypertensive rats (SHRs). The present study aimed to assess the molecular mechanisms related to this effect. Fourteen-month-old maleSHRswere treated intravenously with saline as vehicle (SHR) or esmolol (SHR-E) (300 μg/kg/min). Age-matched vehicle-treated male Wistar-Kyoto (WKY) rats served as controls. After 48 hours of treatment, the hearts were harvested and left ventricular tissue was separated and processed for Western blot analysis to determine the levels of Akt, NF-κB, NFATc4, Creb1, Serca2a, Erk1/2, and Sapk/Jnk. Biomarkers of oxidative stress, such as catalase, protein carbonyls, total thiols, and total antioxidant capacity were evaluated. Esmolol reversed the levels of p-NFATc4, p-Akt, and p-NF-κB in SHRs to the phospholevels of these proteins in WKY rats without modifying p-Erk1/2, p-Sapk/Jnk, p-Creb1, or Serca2a in SHR. Compared with SHR, esmolol increased catalase activity and reduced protein carbonyls without modifying total thiols or total antioxidant capacity. Short-term treatment with esmolol reverses LVH in aged SHRs by downregulation of Akt/NF-κB and NFATc4 activity. Esmolol treatment also increases catalase activity and reduces oxidative stress in SHRs with LVH.

2 June 2016 in Hypertension Research
Verified
Journal Article
Closed access
BQBegoña Quintana-Villamandos
Begoña Quintana-Villamandos
AAAna Arnalich-Montiel
Ana Arnalich-Montiel
SASilvia Arribas
Silvia Arribas
NLNicole Lüneburg
Nicole Lüneburg
RBRainer H Böger
Rainer H Böger
MGMaría Carmen González
María Carmen González

1 November 2016 in European Journal of Pharmacology
Verified
Journal Article
Closed access
BQBegoña Quintana-Villamandos
Begoña Quintana-Villamandos
MGMaría Carmen González
María Carmen González
MDMaría Jesús Delgado-Martos
María Jesús Delgado-Martos
LHLuis Alberto Condezo Hoyos
Luis Alberto Condezo Hoyos
Rainer BögerRainer Böger
Rainer Böger
EDEmilio Delgado-Baeza
Emilio Delgado-Baeza